Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ola Landgren

Showing results (271-280 of 519) with videos related to

Pageof 52
Sort By:
Blood|October 15, 2011
Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based studyEbba K Lindqvist, Lynn R Goldin, Ola Landgren, et al.
European Journal of Haematology|November 19, 2020
A nationwide study on inpatient opportunistic infections in patients with chronic lymphocytic leukemia in the pre-ibrutinib eraVilhjálmur Steingrímsson, Gauti Kjartan Gíslason, Sigrún Þorsteinsdóttir, et al.
Leukemia & Lymphoma|May 13, 2022
Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma: pooled analysis of four single-arm studiesOla Landgren, Dickran Kazandjian, Murielle Roussel, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 24, 2014
Prior autoimmune disease and risk of monoclonal gammopathy of undetermined significance and multiple myeloma: a systematic reviewCharlene M McShane, Liam J Murray, Ola Landgren, et al.
Theranostics|January 9, 2026
Precision radiolabeled B-cell maturation nanobody for targeted PET imaging and radioligand therapy of disseminated multiple myelomaBehnaz Ghaemi, Colleen P Olkowski, Falguni Basuli, et al.
Annals of Hematology|January 8, 2025
Evolution of frontline treatment for multiple myeloma: clinical investigation of quadruplets containing carfilzomib and anti-CD38 monoclonal antibodiesLuciano J Costa, Francesca Gay, Ola Landgren, et al.
Blood|October 8, 2005
Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United StatesOla Landgren, Gloria Gridley, Ingemar Turesson, et al.
International Journal of Cancer|April 8, 2014
Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activityJost K Kloth, Jens Hillengass, Karin Listl, et al.
Blood|September 9, 2010
Racial disparities in incidence and outcome in multiple myeloma: a population-based studyAdam J Waxman, Pamela J Mink, Susan S Devesa, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 3, 2013
Plasma cell neoplasms in US solid organ transplant recipientsEric A Engels, Christina A Clarke, Ruth M Pfeiffer, et al.
Pageof 52

Showing results (271-280 of 519) with videos related to

Sort By:
Pageof 52
Blood|October 15, 2011
Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based studyEbba K Lindqvist, Lynn R Goldin, Ola Landgren, et al.
European Journal of Haematology|November 19, 2020
A nationwide study on inpatient opportunistic infections in patients with chronic lymphocytic leukemia in the pre-ibrutinib eraVilhjálmur Steingrímsson, Gauti Kjartan Gíslason, Sigrún Þorsteinsdóttir, et al.
Leukemia & Lymphoma|May 13, 2022
Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma: pooled analysis of four single-arm studiesOla Landgren, Dickran Kazandjian, Murielle Roussel, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 24, 2014
Prior autoimmune disease and risk of monoclonal gammopathy of undetermined significance and multiple myeloma: a systematic reviewCharlene M McShane, Liam J Murray, Ola Landgren, et al.
Theranostics|January 9, 2026
Precision radiolabeled B-cell maturation nanobody for targeted PET imaging and radioligand therapy of disseminated multiple myelomaBehnaz Ghaemi, Colleen P Olkowski, Falguni Basuli, et al.
Annals of Hematology|January 8, 2025
Evolution of frontline treatment for multiple myeloma: clinical investigation of quadruplets containing carfilzomib and anti-CD38 monoclonal antibodiesLuciano J Costa, Francesca Gay, Ola Landgren, et al.
Blood|October 8, 2005
Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United StatesOla Landgren, Gloria Gridley, Ingemar Turesson, et al.
International Journal of Cancer|April 8, 2014
Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activityJost K Kloth, Jens Hillengass, Karin Listl, et al.
Blood|September 9, 2010
Racial disparities in incidence and outcome in multiple myeloma: a population-based studyAdam J Waxman, Pamela J Mink, Susan S Devesa, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 3, 2013
Plasma cell neoplasms in US solid organ transplant recipientsEric A Engels, Christina A Clarke, Ruth M Pfeiffer, et al.
Pageof 52